Overview

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd